Dermime S, Grignani F, Rogaia D, Liberatore C, Marchesi E, Gambacorti-Passerini C
Division of Experimental Oncology D, Istituto Nazionale Tumori, Milan, Italy.
Leuk Lymphoma. 1995 Jan;16(3-4):289-95. doi: 10.3109/10428199509049768.
Acute promyelocytic leukaemia (APL) cell lines resistant to all-trans retinoic acid (ATRA) have been previously derived from the NB4 cell line, and characterized as having lost the expression of the intact pml/RAR alpha fusion protein. To confirm the association between ATRA-resistance and alteration in the fusion protein at the clonal level, 16 clones were generated from ATRA-resistant APL cell lines. All clones show immunological (HLA class I and II, CD11b and c, CD13 and 33), molecular and growth features similar to the parental cell lines. To investigate whether the irradiation protocol used to generate the previously reported retinoic acid-resistant NB4.306 cell line induced additional alterations that could render these cells able to escape the anti-proliferative effect of retinoic acid (ATRA), an additional ATRA-resistant APL cell line, [NB4.007/6], was generated, under the selective pressure of ATRA, from the NB4 cell line without previous radiation. This cell line shows resistance to the anti-proliferative and differentiating action of ATRA. The NB4.007/6 cell line contains the t(15;17) chromosome translocation, shows the usual pml/RAR alpha hybrid DNA but expresses no detectable amount of the usual pml/RAR alpha protein in Western blot analysis, similarly to the NB4.306 cell line. Finally, the relative resistance to ATRA of NB4.306 and NB4.007/6 was evaluated by comparing the phenotypic (CD11b) changes induced by ATRA in these two lines with those induced in the parental, ATRA-sensitive, NB4 cell line. It is estimated that NB4.306 and NB4.007/6 are about 300 and 70 times less sensitive to ATRA than the original NB4 cell line.
急性早幼粒细胞白血病(APL)对全反式维甲酸(ATRA)耐药的细胞系先前已从NB4细胞系中获得,并被鉴定为失去了完整的PML/RARα融合蛋白的表达。为了在克隆水平上证实ATRA耐药性与融合蛋白改变之间的关联,从对ATRA耐药的APL细胞系中产生了16个克隆。所有克隆在免疫学(HLA I类和II类、CD11b和c、CD13和33)、分子和生长特征方面均与亲代细胞系相似。为了研究用于产生先前报道的抗维甲酸NB4.306细胞系的照射方案是否诱导了其他改变,从而使这些细胞能够逃避维甲酸(ATRA)的抗增殖作用,在没有先前辐射的情况下,在ATRA的选择压力下,从NB4细胞系中产生了另一种对ATRA耐药的APL细胞系[NB4.007/6]。该细胞系对ATRA的抗增殖和分化作用具有抗性。NB4.007/6细胞系含有t(15;17)染色体易位,显示出常见的PML/RARα杂交DNA,但在蛋白质印迹分析中未检测到可检测量的常见PML/RARα蛋白,这与NB4.306细胞系相似。最后,通过比较ATRA在这两个细胞系中诱导的表型(CD11b)变化与在亲代、对ATRA敏感的NB4细胞系中诱导的变化,评估了NB4.306和NB4.007/6对ATRA的相对耐药性。据估计,NB4.306和NB4.007/6对ATRA的敏感性分别比原始NB4细胞系低约300倍和70倍。